# SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

> **NCT05307328** · PHASE2 · COMPLETED · sponsor: **Sparrow Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Cushing's Syndrome I
- Cushing Disease Due to Increased ACTH Secretion
- Cortisol Excess
- Cortisol; Hypersecretion
- Cortisol Overproduction
- Ectopic ACTH Secretion

## Interventions

- **DRUG:** SPI-62
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05307328
- **Lead sponsor:** Sparrow Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05307328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05307328, "SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05307328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*